MOG and myeloid sarcoma: In vivo (experimental MS model) and in vitro studies have shown that anti-MOG CAR-Tregs suppress inflammation and demyelination, anti-MBP CAR-Tregs reduce disease severity, and CAR-Tregs inhibit the proliferation of autoreactive T cells [110].